Related Experiment Video

Updated: May 30, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

[Molecular and genetic aspects of triple negative breast cancer and therapeutic implications]

J Collignon1, I Struman, S Tabruyn

  • 1Service d'Oncologie Médicale, CHU de Liège, Belgique. joelle.collignon@chu.ulg.ac.be

Revue Medicale De Liege
|August 11, 2011
PubMed

Insights

Triple negative breast cancer (TNBC) lacks specific targets, presenting a poor prognosis. Research focuses on molecular characterization and identifying novel biomarkers, such as microRNAs, to develop new therapies for this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Triple negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors.
  • TNBC represents a heterogeneous group of tumors with a generally poor prognosis.
  • The lack of specific molecular targets makes TNBC treatment challenging.

Purpose of the Study:

  • To review recent advancements in understanding the molecular characteristics of TNBC.
  • To explore the potential of novel biomarkers, including microRNAs, for TNBC diagnosis and treatment.
  • To discuss emerging therapeutic strategies targeting various pathways in TNBC.

Main Methods:

  • Review of recent scientific literature on TNBC molecular profiling.
  • Analysis of studies investigating intracellular and extracellular microRNAs as biomarkers.
  • Examination of research on signaling pathways implicated in TNBC development and progression.

Main Results:

  • TNBC heterogeneity necessitates detailed molecular characterization for effective treatment.
  • MicroRNAs (miRNAs) show promise as specific biomarkers for TNBC.
  • Identification of several molecular pathways offers potential targets for new therapeutic interventions.

Conclusions:

  • Further molecular characterization of TNBC is crucial for identifying new therapeutic targets.
  • MicroRNA-based biomarkers could significantly improve TNBC management.
  • Targeting specific molecular pathways holds promise for developing more effective TNBC therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...